US Reschedules Cannabis as ‘Less Dangerous’ , Expanding Patient Access and Boosting Research

In a major policy announcement, the US Department of Justice has announced the reclassification of cannabis from a Schedule 1 drug to a Schedule 3. This has far reaching implications for medical cannabis research and business tax, but does not legalize adult-use consumption at a federal level.